U.S. FDA outlines plan to speed rare disease drug reviews

WASHINGTON (Reuters) - The U.S. Food and Drug Administration plans to reorganize its drug review staff and create a SWAT team to eliminate a backlog of drugs for rare diseases and speed reviews of future applications, it said on Thursday.